“Exceptions that prove the rule”–Why have clinical trials failed to show efficacy of risk factor interventions suggested by observational studies of the dementia-Alzheimer's disease syndrome?

TY - JOUR

T1 - “Exceptions that prove the rule”–Why have clinical trials failed to show efficacy of risk factor interventions suggested by observational studies of the dementia-Alzheimer's disease syndrome?

AU - Breitner, John C.S.

AU - Dodge, Hiroko H.

AU - Khachaturian, Zaven S.

AU - Khachaturian, Ara S.

N1 - Funding Information: This work is partially supported by National Institutes of Health Grant P30AG066518 (in support of HHD's work) and by Pfizer Canada, the Government of Canada, and McGill University (support for JCSB). Hiroko H. Dodge is supported by NIH funding and serves as a consultant for Biogen, Inc. Zaven S. Khachaturian is Editor‐in‐Chief of ; he has grants, contracts, or subawards from the Alzheimer's Association, Berkman Charitable Trust, Arizona State University, consulting fees from Renew Research, Acadia Pharmaceuticals, Biogen, and has leadership/fiduciary roles for Prevent Alzheimer's Disease 2020 and is an employee of KAI. Ara S. Khachaturian is Executive Editor of ; he has grants, contracts, or subawards from the Alzheimer's Association, Berkman Charitable Trust, Arizona State University; consulting fees from Renew Research, Acadia Pharmaceuticals, Eisai, Biogen; and has leadership/fiduciary roles for Prevent Alzheimer's Disease 2020, Care Weekly; and is an employee of KAI. Alzheimer's & Dementia Alzheimer's & Dementia, Alzheimer's & Dementia Translational Research & Clinical Interventions, Alzheimer's & Dementia Diagnosis, Assessment and Disease Monitoring Funding Information: This work is partially supported by National Institutes of Health Grant R01AG051628, R01AG056102, P30AG066518 (in support for HHD) and by Pfizer Canada, the Government of Canada, and McGill University (support for JCSB). HHD is supported by NIH funding and serves as a consultant for Biogen, Inc. and is the founder and CEO of the I-CONNECT foundation (501(c)(3) non-profit organization). Zaven S. Khachaturian is Editor-in-Chief of Alzheimer's & Dementia; he has grants, contracts, or subawards from the Alzheimer's Association, Berkman Charitable Trust, Arizona State University, consulting fees from Renew Research, Acadia Pharmaceuticals, Biogen, and has leadership/fiduciary roles for Prevent Alzheimer's Disease 2020 and is an employee of KAI. Ara S. Khachaturian is Executive Editor of Alzheimer's & Dementia, Alzheimer's & Dementia Translational Research & Clinical Interventions, Alzheimer's & Dementia Diagnosis, Assessment and Disease Monitoring; he has grants, contracts, or subawards from the Alzheimer's Association, Berkman Charitable Trust, Arizona State University; consulting fees from Renew Research, Acadia Pharmaceuticals, Eisai, Biogen; and has leadership/fiduciary roles for Prevent Alzheimer's Disease 2020, Care Weekly; and is an employee of KAI. [Correction added on 21 March 2022, after first online publication: The Acknowledgments section was updated to include additional information for HHD.]

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85125567039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125567039&partnerID=8YFLogxK

U2 - 10.1002/alz.12633

DO - 10.1002/alz.12633

M3 - Editorial

C2 - 35245406

AN - SCOPUS:85125567039

SN - 1552-5260

VL - 18

SP - 389

EP - 392

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 3

ER -